Enter multiple symbols separated by commas

Biotech and Pharmaceuticals Pharmaceuticals


  • Trust in J&J’s Dividend Thursday, 26 Mar 2009 | 7:38 PM ET

    After more than 25 years, this stock is still a Cramer favorite.

  • Goodbye Genentech & Your DNA Thursday, 26 Mar 2009 | 2:29 PM ET

    DNA has always been one of my favorite clever ticker symbols on the biopharma beat. Sure, GENE might've made sense for Genentech if it had been listed on the Nasdaq, but DNA was pretty good. But after today DNA is no more.

  • Did Dendreon Do Itself In? Wednesday, 25 Mar 2009 | 12:34 PM ET

    Oh, the Dendreon investor message boards are on fire! And my inbox has a few sparks. Matthew Herper at Forbes wrote a piece today daring to question the integrity of the all-important data due out sometime next month on DNDN's prostate cancer treatment Provenge.

  • Stop Trading!: Protecting Sears From Shorts Tuesday, 24 Mar 2009 | 3:59 PM ET

    Plus, Cramer discusses credit-card and drug stocks, as well as the housing bottom.

  • Roll Out The Red Carpet! ASCO Goes Hollywood Tuesday, 24 Mar 2009 | 10:45 AM ET

    All of my, ahem, complaining and whining, to put it politely, about the American Society of Clinical Oncology may not have fallen on deaf ears after all.

  • Genentech & Abbott CEOs Roar Monday, 23 Mar 2009 | 3:47 PM ET

    Art Levinson and Miles White are "Kings of the Jungle." At least Barron's thinks they are. The weekly investment periodical picked the pair as the only two from biopharma to make its annual list of the "30 Most Respected CEOs."

  • My Tweets And Your Emails Friday, 20 Mar 2009 | 4:44 PM ET

    My first week on Twitter has gone pretty well. Despite some Twitter trouble (or should that be twubble?) with website capacity, I've picked up more than 75 followers already.

  • GlaxoSmithKline's New Ally For Alli Friday, 20 Mar 2009 | 11:28 AM ET

    Normally, the folks at GlaxoSmithKline keep us tightly in the loop when there's news. So, I'm a bit surprised that it took a "tweet" on Twitter this morning to learn that four days ago the company put out a press release that has "Pharma's Market" written all over it.

  • Pfizer: Turning The Bad Economy Into Good PR? Thursday, 19 Mar 2009 | 11:01 AM ET

    Pfizer announced this morning that it's raising the income levels for uninsured people to qualify for cheaper or free drugs because of the bad economy.

  • How to Get Prescription Drugs for Less Wednesday, 18 Mar 2009 | 5:46 PM ET

    Overpaying for our prescription drugs just feels like a headache no one needs right now, doesn’t it?

  • NEJM Gets At Heart Of Pfizer's/Pharma's Problems Wednesday, 18 Mar 2009 | 5:15 PM ET

    Scientific and medical journals like to keep their distance from the business side of things. That's why I think it's worth noting that a "Perspective" piece--think of it as kind of a newspaper Op-Ed--in "The New England Journal of Medicine" starts by mentioning Pfizer's stock price and its recent proposed acquisition of Wyeth.

  • Sam Waksal Wants Back In Biotech Tuesday, 17 Mar 2009 | 10:55 AM ET
    Sam Waksal

    Despite my repeated invitations for his first post-jailhouse interview on this blog and through one of his contacts, Sam Waksal didn't respond. Given his Manhattan social scene background it should not, perhaps, come as a surprise that the founder of ImClone Systems decided to have his coming-out party in "New York" magazine.

  • Roche Gets Genentech, But At What Price? Monday, 16 Mar 2009 | 12:56 PM ET

    The overwhelming majority of people who have voted in the “Pharma’s Market” poll about the future of Genentech’s execs and top scientists thinks most of them will eventually bolt.

  • I Can’t Get Off Drugs Monday, 16 Mar 2009 | 11:20 AM ET

    Last week was a busy week, to say the least, on the Pharma beat - So I was looking forward to the weekend and escaping all things drug-related. But as fate would have it, it ended up being bookended by references to pharma in a couple of surprising venues.

  • Dendreon Springs Back To Life Friday, 13 Mar 2009 | 1:52 PM ET

    All of a sudden yesterday and today shares of Dendreon  —my favorite biotech story—shot up on heavy volume.

  • Stock Picks Dripping with Cash Friday, 13 Mar 2009 | 11:17 AM ET

    Even when picking stocks, cash is king, according to Wouter Weijand from Fortis Investments, who likes US funeral service company Hillenbrand, Swiss healthcare manufacturer Novartis, and Australia’s ANZ Bank.

  • A Lucky Friday The 13th For Merck Friday, 13 Mar 2009 | 10:48 AM ET

    Shares of Dow component Merck rare getting a nice little shot in the arm this morning on an upgrade by Dr. Tim Anderson at Sanford C. Bernstein. He's putting an "Outperform" or "Buy" rating on MRK and raising his target price three bucks to $30.

  • Just Say Yes to Drugs ... and Drug Stocks! Friday, 13 Mar 2009 | 8:49 AM ET

    Anyone out there who sees hope in the stock market must be on drugs.  And I am: Lipitor and Novasc from Pfizer, Vasotec from Merck, and four other pills, all of which I gobble every day to stop myself from blowing a gasket. So let me say, with some personal pill-popping experience, that this may be a great time to buy drug stocks.

  • Cramer’s Seven Signs This Rally’s Real Thursday, 12 Mar 2009 | 7:32 PM ET

    Even better: Events that could push the Dow up another 1,000 points.

  • Stop Trading!: Billions Change Hands in Pharma Thursday, 12 Mar 2009 | 4:02 PM ET

    Plus, Cramer makes the call on Goldman Sachs, General Electric, Apple, Citigroup and more.